MXPA03010797A - Combinacion de agonista del receptor d2 de dopamina y tiotropio o derivados del mismo para tratamiento de enfermedades obstructivas de vias respiratorias y otras de tipo inflamatorio. - Google Patents

Combinacion de agonista del receptor d2 de dopamina y tiotropio o derivados del mismo para tratamiento de enfermedades obstructivas de vias respiratorias y otras de tipo inflamatorio.

Info

Publication number
MXPA03010797A
MXPA03010797A MXPA03010797A MXPA03010797A MXPA03010797A MX PA03010797 A MXPA03010797 A MX PA03010797A MX PA03010797 A MXPA03010797 A MX PA03010797A MX PA03010797 A MXPA03010797 A MX PA03010797A MX PA03010797 A MXPA03010797 A MX PA03010797A
Authority
MX
Mexico
Prior art keywords
combination
dopamine
receptor agonist
tiotropium
obstructive airways
Prior art date
Application number
MXPA03010797A
Other languages
English (en)
Inventor
Yeadon Michael
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MXPA03010797A publication Critical patent/MXPA03010797A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere a una combinacion de agentes terapeuticos util en el tratamiento de enfermedades obstructivas de las vias respiratorias y otras de tipo inflamatorio que comprende (I) un agonista del receptor D2 de dopamina que es terapeuticamente eficaz en el tratamiento de dichas enfermedades cuando se administra mediante inhalacion; junto con (II) un agente anticolinergico que comprende un miembro seleccionado del grupo que consta de tiotropio y derivados del mismo que es terapeuticamente eficaz en el tratamiento de dichas enfermedades cuando se administra mediante inhalacion; asi como a un metodo de tratamiento de dichas enfermedades obstructivas de las vias respiratorias y otras de tipo inflamatorio que comprende administrar a dicho mamifero mediante inhalacion una cantidad terapeuticamente eficaz de dicha combinacion de agentes terapeuticos; y una composicion farmaceutica que comprende un portador farmaceuticamente aceptable junto con dicha combinacion de agentes terapeuticos; y un envase que contiene una composicion farmaceutica para insertar en un dispositivo capaz del suministro simultaneo o secuencial de dicha composicion farmaceutica en forma de un aerosol o dispersion de polvos secos a dicho mamifero, donde dicho dispositivo es un inhalador de dosis medidas o un inhalador de polvos secos. Se prefiere que dicho componente agonista del receptor D2 de dopamina sea mesilato de bromocriptina, hidrocloruro de naxagolida, cabergolina, mesilato de pergolida, hidrocloruro de quinpirol, o hidrocloruro de ropinirol; y que dicho componente de agente anticolinergico sea bromuro de tiotropio.
MXPA03010797A 2001-05-25 2002-05-23 Combinacion de agonista del receptor d2 de dopamina y tiotropio o derivados del mismo para tratamiento de enfermedades obstructivas de vias respiratorias y otras de tipo inflamatorio. MXPA03010797A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29363001P 2001-05-25 2001-05-25
US30385901P 2001-07-09 2001-07-09
PCT/EP2002/005642 WO2002096422A2 (en) 2001-05-25 2002-05-23 Combination of a dopamine d2-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways

Publications (1)

Publication Number Publication Date
MXPA03010797A true MXPA03010797A (es) 2004-03-02

Family

ID=26968061

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010797A MXPA03010797A (es) 2001-05-25 2002-05-23 Combinacion de agonista del receptor d2 de dopamina y tiotropio o derivados del mismo para tratamiento de enfermedades obstructivas de vias respiratorias y otras de tipo inflamatorio.

Country Status (7)

Country Link
US (1) US20070117788A1 (es)
EP (1) EP1397134A2 (es)
JP (1) JP2004538267A (es)
AU (1) AU2002314101A1 (es)
CA (1) CA2445650A1 (es)
MX (1) MXPA03010797A (es)
WO (1) WO2002096422A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05011225A (es) * 2003-04-18 2005-12-14 Pharmacia & Upjohn Co Llc Politerapias.
US7507745B2 (en) 2004-02-20 2009-03-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on fluorenecarboxylic acid esters and soluble TNF receptor fusion proteins
JP2007523117A (ja) * 2004-02-20 2007-08-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬及びｐｅｇｓｕｎｅｒｃｅｐｔを基にした新規な医薬組成物
DE102004020908A1 (de) * 2004-04-28 2005-11-17 Grünenthal GmbH Substituierte 5,6,7,8,-Tetrahydro-pyrido[4,3-d]pyrimidin-2-yl- und 5,6,7,8,-Tetrahydro-chinazolin-2-yl-Verbindungen
US7923455B2 (en) * 2005-01-28 2011-04-12 Boehringer Ingelheim International Gmbh Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic
KR101278011B1 (ko) * 2005-04-28 2013-06-27 다이닛본 스미토모 세이야꾸 가부시끼가이샤 만성 폐쇄성 폐질환 치료제
CA2622696A1 (en) * 2007-11-05 2009-05-05 Diane Mcintosh Methods and compositions for retarding weight gain associated with use of atypical antipsychotic drugs
EP2285786B1 (en) 2008-06-16 2013-10-09 Merck Patent GmbH Quinoxalinedione derivatives
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100137787A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Delivery devices for modulating inflammation
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100135984A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136095A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US8545878B1 (en) * 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use
BR112015010601B1 (pt) 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
WO2019118528A1 (en) * 2017-12-12 2019-06-20 Arkuda Therapeutics Progranulin modulators and methods of using the same
WO2020214886A1 (en) * 2019-04-17 2020-10-22 Vici Health Sciences LLC Liquid pharmaceutical compositions
CN110806488B (zh) * 2019-12-06 2020-09-25 南京医科大学 Drd5及其激动剂在制备治疗炎症性疾病的药物中的应用
US11446244B2 (en) * 2020-01-17 2022-09-20 Matthew McLeay Compositions containing verteporfin, ribavirin, gemcitabine, or combinations thereof and methods of use for treating COVID-19, cancer, or non cancer diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509119A (ja) * 1998-01-13 2002-03-26 アストラゼネカ ユーケイ リミテッド ドーパミン（Ｄ２）レセプターアゴニスト活性を有する化合物およびβ２−アドレナリンレセプターアゴニスト活性を有する化合物（Ｂ）を含有する薬学的組成物
UA75375C2 (en) * 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods

Also Published As

Publication number Publication date
JP2004538267A (ja) 2004-12-24
EP1397134A2 (en) 2004-03-17
WO2002096422A2 (en) 2002-12-05
CA2445650A1 (en) 2002-12-05
WO2002096422A3 (en) 2003-02-20
US20070117788A1 (en) 2007-05-24
AU2002314101A1 (en) 2002-12-09

Similar Documents

Publication Publication Date Title
MXPA03010797A (es) Combinacion de agonista del receptor d2 de dopamina y tiotropio o derivados del mismo para tratamiento de enfermedades obstructivas de vias respiratorias y otras de tipo inflamatorio.
MXPA03010791A (es) Combinacion de inhibidor de pde4 y tiotropio a sus derivados para tratamiento de enfermedades obstructivas de vias respiratorias y de otras enfermedades inflamatorias.
WO2002094273A3 (en) Combination of an adenosine a2a-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways
NZ585856A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
AU2004216472B2 (en) Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients
JP2016040316A5 (es)
NZ585857A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
NZ593695A (en) Alkaloid aminoester derivatives and medicinal composition thereof
RU2013119938A (ru) Фармацевтическая композиция
JP2006188534A (ja) 抗コリン作用化合物及びβ−擬似剤に基づく新規医薬組成物
TNSN06277A1 (en) Pharmaceutical formulations for dry powder inhalers comprising a low-dosage strength active ingredient
RU2008124833A (ru) Лечение астмы и хронического обструктивного заболевания легких с использованием тройных комбинаций
CY1110625T1 (el) Μεθοδος για την χορηγηση τιοτροπιου
NO20051463L (no) Inhaleringssammensetninger med hoy legemiddelandel
MXPA05009629A (es) Composiciones que contienen trospio.
WO2011136754A1 (en) A medicament developed for the treatment of respiratory diseases
EP2563364A1 (en) Combination of carmoterol and fluticasone for use in the treatment respiratory diseases
CA2457717A1 (en) Use of compounds in a dry powder inhaler
NZ597102A (en) Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists
CA2527178A1 (en) New long-acting drug combinations for the treatment of respiratory complaints
PL214869B1 (pl) Synergistyczna kombinacja zawierajaca roflumilast i (R, R)-formoterol
BRPI0410173A (pt) composição farmacêutica para a prevenção e tratamento da viciação em nicotina em um mamìfero
TW201605440A (zh) 阿地銨之新用途
KR20030024582A (ko) 제형